Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.56 |
| ▸ | SYK | P43405 | 6/20 | 0.56 |
| ▸ | SIK1 | P57059 | 2/20 | 0.54 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.54 |
| ▸ | SIK3 | Q9Y2K2 | 2/20 | 0.54 |
| ▸ | BCL6 | P41182 | 1/20 | 0.53 |
| ▸ | BTK | Q06187 | 3/20 | 0.52 |
| ▸ | JAK3 | P52333 | 3/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | FLT3 | P36888 | 2/20 | 0.52 |
| ▸ | CSF1R | P07333 | 2/20 | 0.52 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.52 |
| ▸ | CDC7 | O00311 | 1/20 | 0.52 |
| ▸ | PLK4 | O00444 | 1/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495111 | 0.93 | EGFR (0.61) | EGFRSYKSIK1SIK2SIK3 | |
| SCHEMBL3496601 | 0.90 | ALK (0.52) | EGFRSYKSIK1SIK2SIK3 | |
| SCHEMBL5105140 | 0.88 | BRD4 (0.61) | EGFRSYKSIK2SIK3BTK | |
| SCHEMBL3494949 | 0.88 | BCL6 (0.64) | EGFRSYKSIK1SIK2SIK3 | |
| SCHEMBL3497333 | 0.87 | EGFR (0.54) | EGFRSYKSIK1SIK2SIK3 | |
| SCHEMBL3497282 | 0.86 | SYK (0.54) | EGFRSYKSIK1SIK2SIK3 | |
| SCHEMBL12952094 | 0.85 | SYK (0.59) | EGFRSYKSIK1SIK2SIK3 | |
| SCHEMBL3497092 | 0.85 | BCL6 (0.54) | EGFRSYKSIK1SIK2SIK3 | |
| Hydrochloric Acid SCHEMBL27662179 | 0.84 | SYK (0.61) | EGFRSYKSIK1SIK2SIK3 | |
| Hydrochloric Acid SCHEMBL27662239 | 0.83 | SYK (0.58) | EGFRSYKSIK1SIK2SIK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452879-B2 | N4-(1-tert-Butoxycarbonylazetidin-3-yl)-5-fluoro-N2-(4-morpholinophenyl)-2,4-pyrimidinediamine; signal transduction cascade inhibitor; Fc receptors for IgE (\"Fc epsilon RI\") and IgG (\"Fc gamma RI\") antagonist; autoimmune diseases, antiinflammatory agent; rheumatoid arthritis, multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2008-11-18 | — | — | US | claimed |
| US-8993585-B2 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | EGFR 1181/4885SYK 460/4885SIK1 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.